|
1
|
Jin Y, Lin Q, Fei H, Xue L, Li L, Xi Q and
Jiang H: Bioinformatics analysis of potential therapeutic targets
and prognostic biomarkers amid CXC chemokines in ovarian carcinoma
microenvironment. J Oncol. 2021:88595542021. View Article : Google Scholar
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keyvani V, Farshchian M, Esmaeili SA, Yari
H, Moghbeli M, Nezhad SK and Abbaszadegan MR: Ovarian cancer stem
cells and targeted therapy. J Ovarian Res. 12:1202019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G
and Jin WL: Immunotherapy for ovarian cancer: Adjuvant,
combination, and neoadjuvant. Front Immunol. 11:5778692020.
View Article : Google Scholar
|
|
5
|
Gaona-Luviano P, Medina-Gaona LA and
Magaña-Pérez K: Epidemiology of ovarian cancer. Chin Clin Oncol.
9:472020. View Article : Google Scholar
|
|
6
|
Cortez AJ, Tudrej P, Kujawa KA and
Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother
Pharmacol. 81:17–38. 2018. View Article : Google Scholar
|
|
7
|
Bogani G, Lopez S, Mantiero M, Ducceschi
M, Bosio S, Ruisi S, Sarpietro G, Guerrisi R, Brusadelli C,
Dell'Acqua A, et al: Immunotherapy for platinum-resistant ovarian
cancer. Gynecol Oncol. 158:484–488. 2020. View Article : Google Scholar
|
|
8
|
Arora T, Mullangi S and Lekkala MR:
Ovarian cancer. StatPearls [Internet]. StatPearls Publishing;
Treasure Island, FL: 2022
|
|
9
|
Zhang M, Cheng S, Jin Y, Zhao Y and Wang
Y: Roles of CA125 in diagnosis, prediction, and oncogenesis of
ovarian cancer. Biochim Biophys Acta Rev Cancer. 1875:1885032021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Atallah GA, Abd Aziz NH, Teik CK, Shafiee
MN and Kampan NC: New predictive biomarkers for ovarian cancer.
Diagnostics (Basel). 11:4652021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gonzalez-Aparicio M and Alfaro C:
Significance of the IL-8 pathway for immunotherapy. Hum Vaccin
Immunother. 16:2312–2317. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marchewka Z, Gielniak M and Piwowar A: The
role of selected mediators of inflammation in the pathogenesis of
cancer. Postepy Hig Med Dosw. 72:175–183. 2018. View Article : Google Scholar
|
|
13
|
Łukaszewicz-Zając M, Pączek S, Mroczko P
and Kulczyńska-Przybik A: The significance of CXCL1 and CXCL8 as
Well as their specific receptors in colorectal cancer. Cancer Manag
Res. 12:8435–8443. 2020. View Article : Google Scholar
|
|
14
|
Turnquist C, Ryan BM, Horikawa I, Harris
BT and Harris CC: Storms in cancer and COVID-19. Cancer Cell.
38:598–601. 2020. View Article : Google Scholar
|
|
15
|
Kumar S, O'Malley J, Chaudhary AK, Inigo
JR, Yadav N, Kumar R and Chandra D: Hsp60 and IL-8 axis promotes
apoptosis resistance in cancer. Br J Cancer. 121:934–943. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Friedman A and Liao KL: The role of the
cytokines IL-27 and IL-35 in cancer. Math Biosci Eng. 12:1203–1217.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Groblewska M, Litman-Zawadzka A and
Mroczko B: The role of selected chemokines and their receptors in
the development of gliomas. Int J Mol Sci. 21:37042020. View Article : Google Scholar
|
|
18
|
Lane D, Matte I, Rancourt C and Piché A:
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian
cancer patients. BMC Cancer. 11:2102011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T,
Chen Y, Han X and Wu K: The CXCL8-CXCR1/2 pathways in cancer.
Cytokine Growth Factor Rev. 31:61–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ha H, Debnath B and Neamati N: Role of the
CXCL8-CXCR1/2 axis in cancer and inflammatory diseases.
Theranostics. 7:1543–1588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Antonosante A, Brandolini L, d'Angelo M,
Benedetti E, Castelli V, Maestro MD, Luzzi S, Giordano A, Cimini A
and Allegretti M: Autocrine CXCL8-dependent invasiveness triggers
modulation of actin cytoskeletal network and cell dynamics. Aging
(Albany NY). 12:1928–1951. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gales D, Clark C, Manne U and Samuel T:
The chemokine CXCL8 in carcinogenesis and drug response. ISRN
Oncol. 2013:8591542013.
|
|
24
|
Nolen BM and Lokshin AE: Biomarker testing
for ovarian cancer: Clinical utility of multiplex assays. Mol Diagn
Ther. 17:139–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar
|
|
26
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jia D, Nagaoka Y, Katsumata M and Orsulic
S: Inflammation is a key contributor to ovarian cancer cell
seeding. Sci Rep. 8:123942018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Savant SS, Sriramkumar S and O'Hagan HM:
The role of inflammation and inflammatory mediators in the
development, progression, metastasis, and chemoresistance of
epithelial ovarian cancer. Cancers (Basel). 10:2512018. View Article : Google Scholar
|
|
29
|
Wen J, Zhao Z, Huang L, Wang L, Miao Y and
Wu J: IL-8 promotes cell migration through regulating EMT by
activating the Wnt/β-catenin pathway in ovarian cancer. J Cell Mol
Med. 24:1588–1598. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Browne A, Sriraksa R, Guney T, Ramac N,
Van Noordena S, Curryc E, Gabrac H, Stronachc E and El-Bahrawy M:
Differential expression of IL-8 and IL-8 receptors in benign,
borderline and malignant ovarian epithelial tumours. Cytokine.
64:413–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Crispim PCA, Jammal MP, Antão PKA, Micheli
DC, Tavares-Murta BM, Murta EFC and Nomelini RS: IL6, IL8, and IL10
in the distinction of malignant ovarian neoplasms and
endometriomas. Am J Reprod Immunol. 84:e133092020. View Article : Google Scholar
|
|
32
|
Zhang L, Liu W, Wang X, Wang X and Sun H:
Prognostic value of serum IL-8 and IL-10 in patients with ovarian
cancer undergoing chemotherapy. Oncol Lett. 17:2365–2369. 2019.
|
|
33
|
Yang M, Zhang G, Wang Y, He M, Xu Q, Lu J,
Liu H and Xu C: Tumour-associated neutrophils orchestrate
intratumoural IL-8-driven immune evasion through Jagged2 activation
in ovarian cancer. Br J Cancer. 123:1404–1416. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thongchot S, Jamjuntra P, Therasakvichya
S, Warnnissorn M, Ferraresi A, Thuwajit P, Isidoro C and Thuwajit
C: Interleukin-8 released by cancer-associated fibroblasts
attenuates the autophagy and promotes the migration of ovarian
cancer cells. Int J Oncol. 58:142021. View Article : Google Scholar
|
|
35
|
Alfaro C, Teijeira A, Oñate C, Pérez G,
Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A,
Rodriguez-Paulete A, et al: Tumor-produced interleukin-8 attracts
human myeloid-derived suppressor cells and elicits extrusion of
neutrophil extracellular traps (NETs). Clin Cancer Res.
22:3924–3936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Henriques TB, Dos Santos DZ, Dos Santos
Guimarães I, Tessarollo NG, Lyra-Junior PCM, Mesquita P, Pádua D,
Amaral AL, Cavadas B, Pereira L, et al: Inhibition of CXCR2 plays a
pivotal role in re-sensitizing ovarian cancer to cisplatin
treatment. Aging (Albany NY). 13:13405–13420. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Duckworth C, Zhang L, Carroll SL, Ethier
SP and Cheung HW: Overexpression of GAB2 in ovarian cancer cells
promotes tumor growth and angiogenesis by upregulating chemokine
expression. Oncogene. 35:4036–4047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stronach EA, Cunnea P, Turner C, Guney T,
Aiyappa R, Jeyapalan S, de Sousa CH, Browne A, Magdy N, Studd JB,
et al: The role of interleukin-8 (IL-8) and IL-8 receptors in
platinum response in high grade serous ovarian carcinoma.
Oncotarget. 6:31593–31603. 2015. View Article : Google Scholar
|
|
39
|
Taki M, Abiko K, Baba T, Hamanishi J,
Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura
E, et al: Snail promotes ovarian cancer progression by recruiting
myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat
Commun. 9:16852018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Han ZJ, Li YB, Yang LX, Cheng HJ, Liu X
and Chen H: Roles of the CXCL8-CXCR1/2 axis in the tumor
microenvironment and immunotherapy. Molecules. 27:1372021.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liubomirski Y, Lerrer S, Meshel T,
Rubinstein-Achiasaf L, Morein D, Wiemann S, Körner C and Ben-Baruch
A: Tumor-stroma-inflammation networks promote pro-metastatic
chemokines and aggressiveness characteristics in triple-negative
breast cancer. Front Immunol. 10:7572019. View Article : Google Scholar
|
